Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01902576 · ClinicalTrials.gov registry record
Chronic GVHD Response Measures Validation
A clinical trial of Graft Vs Host Disease, sponsored by Fred Hutchinson Cancer Center.
- Active
- Registry status
- 383
- Enrollment target
- 1
- Study location
NCT01902576: Active study of Graft Vs Host Disease, sponsored by Fred Hutchinson Cancer Center.
NCT01902576 is a study of Graft Vs Host Disease that is active but no longer recruiting, run by Fred Hutchinson Cancer Center. The registered enrollment target is 383 participants, above the 127-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (202% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01902576, a study of Graft Vs Host Disease, is active but no longer recruiting, sponsored by Fred Hutchinson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 383 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to develop and validate endpoint measures that can accurately determine whether patients are responding to treatment for chronic Graft-versus-Host Disease (GVHD). Hopefully, this will also lead to being better able to predict which patients will respond to what therapies.
Primary Outcome
This measure is intended to capture impairments caused by chronic GVHD. We expect that change in the CGVHD-AI could be used to measure treatment response because it will correlate with clinically significant changes reported by physicians and patients. The CGVHD-AI would be most appropriate for use in clinical trials where the goal is symptom relief and decreased disease activity.
Conditions Studied
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2013-06 |
| Est. Completion | 2027-02 |
What the registry record for NCT01902576 still lists
NCT01902576 is an observational study that tracks outcomes without assigning an intervention. The registered 383 participants enrollment target is mid-sized for trials with a published cap, above the 127-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (202% higher).
The record links to 1 condition, with Graft Vs Host Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01902576 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT01902576 about?
NCT01902576 is a clinical study titled "Chronic GVHD Response Measures Validation". The purpose of this study is to develop and validate endpoint measures that can accurately determine whether patients are responding to treatment for chronic Graft-versus-Host Disease (GVHD). Hopefully, this will also lead to being better able to predict which patients will respond to what therapies...
What is the current status of trial NCT01902576?
This trial is currently active not recruiting. The enrollment target is 383 participants. The study started on 2013-06. Estimated completion is 2027-02.
What conditions does trial NCT01902576 study?
This clinical trial studies the following conditions: Graft Vs Host Disease.
Who is sponsoring clinical trial NCT01902576?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01902576 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01902576's enrollment target sits among peer trials
383 4th of 36 higher than 33 of 36 other Graft Vs Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graft Vs Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
RECRUITING
-
Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
RECRUITING · NA
-
IS-free Treg HaploHCT
RECRUITING · Phase 1
-
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 2
-
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
RECRUITING · Phase 1
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06056830 · 383 participants · Phase 3
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- NCT06277661 · 384 participants · NA
The Mom and Infant Outcomes (MOMI) Study
- NCT06372964 · 384 participants · Phase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
- NCT06501040 · 384 participants · NA
Increasing Knowledge and Interest in Cancer Clinical Trials
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia